Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

In one of the priciest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh, for roughly $10 billion.

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

If it weren’t for the Interventional Pulmonology team at Geisinger Medical Center and the endobronchial valve procedure, ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

Please provide your email address to receive an email when new articles are posted on . Data were derived from Baldomero AK, et al. JAMA Netw Open. 2025;doi:10.1001 ...